<p>(A) Schematic overview of the experimental setup. Starting with streptomycin-pretreatment one day prior to infection with the <i>S.</i> Tm<sup>WT</sup> WITS cocktail in a dilution of 1∶7000, Gr1<sup>+</sup>-cells (mostly neutrophilic granulocytes) were depleted by daily i.p. injection of 100 µg of anti-mouse-Gr1-antibody. The control group was injected with an equal volume of PBS. (B) Successful reduction in Ly6C<sup>+</sup> Ly6G<sup>+</sup> cells in the murine blood was verified daily using a flow cytometry assay. A representative blot is given in panel B. (C) The cecal <i>S.</i> Tm population size was monitored in the Gr1<sup>+</sup>-cell depleted mice and the control group and organ loads and cecum pathology of respective animals were...
<p>White blood cell composition and total cell count in blood from WT and S100A9 KO mice, 24 and 48 ...
<p>A. Brightfield microscopy of representative spleen sections from day 9 and 30 sRBC immunized WT a...
<p>(A) A schematic view of SRBC immunization and anti-CD40L-TM treatment protocol: a cohort of BALB/...
<p>Streptomycin-pretreated C57BL/6 mice were gavaged with a mixture of 7 WITS strains in equal ratio...
<p>BALB/c (white bars), BALB/c DEREG (black bars), C57BL/6 (light grey bars), and C57BL/6 DEREG (dar...
(B) WT or TLR9 mice received 500 μg anti-GR1 antibody or isotype control 24 and 2 h before CLP, and ...
<p>Streptomycin-pretreated C57BL/6 mice were orally infected with a WITS cocktails in the dilution 1...
<p>Six- to eight-week-old female mice were treated with 450 mg/L of streptomycin for 2 days in their...
<p>Infected wild type (WT) and CCR2-DTR mice were treated with DT beginning at week 6 of infection, ...
<p>(<b>A</b>) Splenocytes from DT-treated control (black symbols) and DC-depleted (red symbols) mice...
<p><b>(A)</b> Analysis of myeloid subsets in the spleen of infected <i>Fzd6</i><sup>-/-</sup> (KO) a...
<p><b>(A)</b> Analysis of bone marrow myeloid subsets infected <i>Fzd6</i><sup>-/-</sup> (KO) and <i...
<p>(A) Levels of CCL3 mRNA were increased in liver tissue of infected mice (ALA) compared with sham-...
<p>(A) Effective depletion of inflammatory monocytes (Ly6C<sup>hi</sup>Ly6G<sup>-</sup>) or neutroph...
<p>(A) 5x10<sup>4</sup> naïve OT-I cells from C57BL/6 mice were transferred into 8-10 week old B6.SJ...
<p>White blood cell composition and total cell count in blood from WT and S100A9 KO mice, 24 and 48 ...
<p>A. Brightfield microscopy of representative spleen sections from day 9 and 30 sRBC immunized WT a...
<p>(A) A schematic view of SRBC immunization and anti-CD40L-TM treatment protocol: a cohort of BALB/...
<p>Streptomycin-pretreated C57BL/6 mice were gavaged with a mixture of 7 WITS strains in equal ratio...
<p>BALB/c (white bars), BALB/c DEREG (black bars), C57BL/6 (light grey bars), and C57BL/6 DEREG (dar...
(B) WT or TLR9 mice received 500 μg anti-GR1 antibody or isotype control 24 and 2 h before CLP, and ...
<p>Streptomycin-pretreated C57BL/6 mice were orally infected with a WITS cocktails in the dilution 1...
<p>Six- to eight-week-old female mice were treated with 450 mg/L of streptomycin for 2 days in their...
<p>Infected wild type (WT) and CCR2-DTR mice were treated with DT beginning at week 6 of infection, ...
<p>(<b>A</b>) Splenocytes from DT-treated control (black symbols) and DC-depleted (red symbols) mice...
<p><b>(A)</b> Analysis of myeloid subsets in the spleen of infected <i>Fzd6</i><sup>-/-</sup> (KO) a...
<p><b>(A)</b> Analysis of bone marrow myeloid subsets infected <i>Fzd6</i><sup>-/-</sup> (KO) and <i...
<p>(A) Levels of CCL3 mRNA were increased in liver tissue of infected mice (ALA) compared with sham-...
<p>(A) Effective depletion of inflammatory monocytes (Ly6C<sup>hi</sup>Ly6G<sup>-</sup>) or neutroph...
<p>(A) 5x10<sup>4</sup> naïve OT-I cells from C57BL/6 mice were transferred into 8-10 week old B6.SJ...
<p>White blood cell composition and total cell count in blood from WT and S100A9 KO mice, 24 and 48 ...
<p>A. Brightfield microscopy of representative spleen sections from day 9 and 30 sRBC immunized WT a...
<p>(A) A schematic view of SRBC immunization and anti-CD40L-TM treatment protocol: a cohort of BALB/...